

A Review on Transdermal Drug Delivery Systems in Chronic Pain and Neuropathic Pain Management

Awan Kumar Pandey^{1,*} and Brajesh Garg²

¹⁻² Dr. Preeti Global University, Shivpuri - 473665, M.P. India

*Corresponding Author: Awan Kumar Pandey, Email: awankumarpandey.pgu@gmail.com

Received: 09/07/2026; Revised: 28/07/2026; Accepted: 16/08/2026; Published: 30/09/2026.

DOI: <https://doi.org/10.69996/fmep.2026020>.

Abstract: Chronic pain and neuropathic pain are major healthcare concerns worldwide due to their high prevalence, complex pathophysiology, and significant impact on patient quality of life. Conventional oral analgesic therapies are often limited by poor patient compliance, gastrointestinal disturbances, fluctuating plasma drug levels, and systemic toxicity. Transdermal drug delivery systems (TDDS) have gained considerable attention as an alternative therapeutic approach for the management of chronic and neuropathic pain. This review discusses the pathophysiology and classification of chronic pain, with particular emphasis on neuropathic pain conditions such as diabetic peripheral neuropathy and post-herpetic neuralgia. The review highlights the advantages of transdermal drug delivery over conventional routes, including sustained drug release, improved bioavailability, reduced systemic side effects, and enhanced patient adherence. Various formulation approaches, polymers, permeation enhancers, and evaluation parameters employed in the development of transdermal patches are also discussed. Furthermore, the review summarizes recent advancements in transdermal technologies including matrix patches, reservoir systems, microneedles, iontophoresis, and nanocarrier-based delivery systems. The therapeutic potential and limitations of currently available transdermal analgesic formulations are critically analyzed. The study concludes that transdermal drug delivery represents a promising and patient-centric strategy for effective chronic pain management and warrants further research for improved clinical applications.

Keywords: Microneedles, Iontophoresis, Transdermal Drug Delivery Systems.

1. Introduction

Pain is one of the most common reasons for medical consultation and significantly contributes to physical disability, emotional distress, and socioeconomic burden worldwide. Chronic pain persists beyond the normal healing period and often lacks a protective physiological function. Neuropathic pain, a major subtype of chronic pain, results from damage or disease affecting the somatosensory nervous system and is characterized by abnormal sensory processing [1-4].

Neuropathic pain conditions such as diabetic peripheral neuropathy (DPN) and post-herpetic neuralgia (PHN) are associated with symptoms including burning pain, tingling sensations, hyperalgesia, and allodynia. These conditions substantially impair health-related quality of life by affecting sleep, mood, mobility, and daily functioning [5-8]. Despite the availability of several pharmacological agents, effective treatment remains challenging due to inadequate pain control and adverse effects associated with long-term therapy [9-12].

Traditional oral drug delivery systems often exhibit limitations including hepatic first-pass metabolism, gastrointestinal irritation, variable absorption, and frequent dosing schedules. These drawbacks have stimulated interest in alternative drug delivery approaches capable of providing sustained therapeutic effects with minimal systemic toxicity [13-19]. Transdermal



drug delivery systems have emerged as an important advancement in pharmaceutical technology due to their ability to deliver drugs across the skin directly into systemic circulation [20-22].

Transdermal patches provide several clinical advantages such as non-invasive administration, prolonged drug release, improved bioavailability, reduced dosing frequency, and enhanced patient compliance. Advances in polymer technology, penetration enhancers, and novel delivery approaches have expanded the applicability of TDDS in pain management. Several analgesic drugs including lidocaine, fentanyl, buprenorphine, diclofenac, and ketoprofen have been successfully formulated into transdermal systems for clinical use [23-29].

The present review aims to provide a comprehensive overview of transdermal drug delivery systems for chronic and neuropathic pain management, focusing on their therapeutic potential, formulation strategies, mechanisms of skin permeation, and recent technological developments.

2. Literature Review

Chronic pain is a major public health concern affecting millions worldwide and significantly reducing physical, emotional, and social well-being. Conventional oral drug delivery remains the most common therapeutic approach; however, it often produces systemic side effects, poor bioavailability, and inconsistent therapeutic responses due to hepatic first-pass metabolism and variable gastrointestinal absorption [30-32].

Transdermal drug delivery systems have gained considerable attention as an alternative strategy for chronic pain management because they allow controlled drug release and prolonged therapeutic action. TDDS provide several advantages, including avoidance of gastrointestinal degradation, maintenance of steady plasma drug concentrations, reduced dosing frequency, and improved patient compliance [33-35].

The skin functions as an effective protective barrier, primarily because of the stratum corneum. Consequently, only drugs with appropriate molecular weight, lipophilicity, and potency are suitable candidates for passive transdermal delivery. To improve drug permeation, various enhancement techniques have been explored, including chemical enhancers, ultrasound, electroporation, microneedles, and nanocarrier-based systems [36-37].

Polymeric materials play a critical role in determining the performance of transdermal patches. Hydrophilic polymers facilitate drug diffusion, whereas hydrophobic polymers help sustain drug release. Combination polymer matrices are commonly employed to achieve optimum release profiles and mechanical properties. Studies have shown that HPMC, PVP, Ethyl Cellulose, and Eudragit polymers provide suitable matrix characteristics for analgesic drug delivery.

Significant research has focused on transdermal delivery of pain-relieving drugs such as fentanyl, buprenorphine, diclofenac, ketoprofen, lidocaine, and capsaicin. Fentanyl patches have demonstrated effective management of severe chronic pain by maintaining constant plasma levels over extended periods. Lidocaine patches are particularly useful in localized neuropathic pain conditions such as post-herpetic neuralgia due to their targeted action and low systemic toxicity.

Recent developments in nanotechnology have further enhanced transdermal drug delivery. Nanoemulsions, liposomes, ethosomes, and solid lipid nanoparticles improve drug solubility and penetration across the skin barrier. These advanced carriers enhance therapeutic efficacy while reducing irritation and systemic exposure.

Evaluation of TDDS includes assessment of physicochemical parameters, mechanical strength, drug content uniformity, moisture handling capacity, and in vitro release characteristics.

Skin irritation studies and stability testing are also essential for ensuring safety and efficacy of the developed formulations.

Overall, transdermal systems represent a promising approach for chronic pain therapy. Ongoing advances in formulation science, biomaterials, and permeation technologies continue to improve the effectiveness of transdermal analgesic systems.

3. Methodology

A. Research Design

The study was designed as a systematic review-based research investigation focusing on transdermal drug delivery systems used in chronic and neuropathic pain management. Relevant published literature was collected, analyzed, and critically evaluated.

B. Literature Search Strategy

A comprehensive literature search was conducted using scientific databases including:

- PubMed
- Scopus
- Google Scholar
- ScienceDirect

Keywords used for the search included:

- “Transdermal drug delivery systems”
- “Neuropathic pain”
- “Chronic pain therapy”
- “Transdermal patches”
- “Pain management”
- “Controlled drug delivery”
- “Polymeric patches”
- “Skin permeation enhancers”

Research articles, review papers, clinical studies, and pharmaceutical reports published between 2000 and 2025 were included in the study.

C. Inclusion Criteria

The following studies were included:

- Research related to transdermal drug delivery systems
- Studies involving chronic or neuropathic pain management
- Articles discussing formulation, evaluation, and therapeutic applications
- Peer-reviewed English-language publications

D. Exclusion Criteria

The following studies were excluded:

- Non-English publications
- Duplicate studies
- Studies unrelated to pain management
- Articles lacking adequate scientific data

E. Data Collection

Relevant data extracted from selected studies included:

- Drug candidates used in transdermal systems
- Types of polymers and permeation enhancers
- Preparation methods
- Evaluation parameters
- Drug release and permeation characteristics

- Clinical efficacy and safety profiles

F. Data Analysis

Collected information was systematically categorized and analyzed under the following headings:

- Classification of pain conditions
- Mechanism of transdermal drug delivery
- Formulation approaches
- Evaluation techniques
- Advantages and limitations of TDDS
- Recent advances in transdermal technologies

Comparative analysis of different formulation strategies and therapeutic outcomes was performed to identify recent trends and research gaps.

G. Ethical Considerations

All data utilized in the review were obtained from published scientific literature. Proper citation and referencing were maintained throughout the study to avoid plagiarism and ensure academic integrity.

H. Outcome Assessment

The effectiveness of transdermal systems was assessed based on:

- Sustained drug release capability
- Improved patient compliance
- Reduced systemic adverse effects
- Enhanced bioavailability
- Clinical effectiveness in chronic pain management

The review findings were interpreted to evaluate the future scope and therapeutic potential of transdermal drug delivery systems in pain therapy.

3. Results and Discussion

A. Evaluation of Novel Transdermal Drug Delivery Approaches

Recent advancements in transdermal drug delivery systems have significantly improved the therapeutic management of chronic and neuropathic pain. Modern transdermal technologies such as matrix patches, reservoir systems, microneedles, iontophoresis, sonophoresis, nano-carriers, and hydrogel-based systems have demonstrated improved drug permeation, enhanced bioavailability, and prolonged therapeutic action.

Comparative evaluation of conventional oral dosage forms and advanced transdermal systems revealed that transdermal delivery minimizes systemic fluctuations in drug concentration and reduces gastrointestinal side effects. The ability to maintain steady plasma drug levels contributes to improved analgesic efficacy and patient adherence.

B. Role of Polymers in Controlled Drug Release

Polymers play a significant role in determining the performance of transdermal patches. Hydrophilic polymers such as HPMC and polyvinyl alcohol (PVA) were found to facilitate rapid hydration and swelling, thereby enhancing drug release. Hydrophobic polymers including ethyl cellulose and Eudragit sustained the release profile by forming diffusion barriers.

Polymer combinations demonstrated improved flexibility, mechanical stability, and controlled release characteristics. Studies indicated that optimized polymer ratios resulted in sustained drug release for up to 24 hours without compromising patch integrity.

C. Permeation Enhancement Strategies

One of the major challenges in transdermal drug delivery is the barrier property of the stratum corneum. Various permeation enhancement techniques have therefore been investigated to improve transdermal flux.

Chemical permeation enhancers such as oleic acid, dimethyl sulfoxide, propylene glycol, and terpenes showed significant enhancement in drug permeation by altering skin lipid organization. Physical enhancement techniques including iontophoresis and microneedles effectively increased skin permeability and facilitated delivery of drugs with poor passive diffusion characteristics.

Nanotechnology-based systems such as liposomes, ethosomes, nanoemulsions, and nanoparticles demonstrated improved skin penetration, targeted delivery, and enhanced therapeutic efficacy in chronic pain conditions.

D. Therapeutic Effectiveness in Chronic Pain Conditions

Transdermal systems have demonstrated promising outcomes in various chronic pain disorders including diabetic neuropathy, post-herpetic neuralgia, arthritis, and musculoskeletal pain.

Clinical observations suggest that sustained transdermal administration improves pain control while minimizing systemic toxicity commonly associated with oral analgesics and opioids. Patients receiving transdermal therapy reported better compliance due to non-invasive administration, ease of application, and reduced dosing frequency.

The transdermal route also avoids hepatic first-pass metabolism, thereby improving bioavailability of several analgesic drugs. This contributes to dose reduction and lowers the risk of adverse drug reactions.

E. Limitations and Challenges

Despite significant advancements, certain limitations continue to affect transdermal drug delivery systems. Drugs with high molecular weight, poor lipid solubility, or high therapeutic dose requirements may exhibit limited skin permeability.

Skin irritation, variability in skin permeability among individuals, adhesive failure, and formulation instability are additional challenges associated with transdermal systems. Environmental factors such as temperature and humidity may also influence drug release and patch adhesion.

5. Discussion

The findings of the present review highlight the growing importance of transdermal drug delivery systems in chronic pain management. Advances in polymer science, nanotechnology, and permeation enhancement techniques have substantially improved the efficiency and therapeutic potential of transdermal formulations.

Controlled and sustained drug release achieved through optimized polymeric matrices helps maintain stable plasma drug concentrations and reduces dosing frequency. This improves patient compliance, particularly in chronic conditions requiring long-term therapy.

The incorporation of chemical and physical permeation enhancers has addressed one of the major limitations of transdermal delivery by improving drug transport across the skin barrier. Emerging technologies such as microneedles and nanoparticle-based carriers have expanded the range of drugs suitable for transdermal administration.

Clinical evidence supports the use of transdermal systems in neuropathic and chronic pain conditions due to their ability to reduce systemic side effects, bypass gastrointestinal degradation, and improve therapeutic efficacy. However, formulation optimization remains essential to overcome challenges related to skin irritation, permeability variability, and stability.

Future research should focus on development of smart transdermal systems incorporating responsive polymers, nano-carriers, and personalized drug delivery approaches. Integration of advanced technologies with transdermal systems may further enhance therapeutic outcomes and revolutionize pain management strategies.

In conclusion, transdermal drug delivery systems represent an effective, safe, and innovative alternative to conventional pain therapies, offering considerable potential for improving quality of life in patients suffering from chronic pain disorders.

6. Conclusion

The present review demonstrates that recent advancements in transdermal drug delivery technologies have significantly improved the management of chronic and neuropathic pain conditions. Modern transdermal systems provide controlled and sustained drug release, improved bioavailability, reduced systemic side effects, and enhanced patient compliance compared to conventional oral therapies.

The use of advanced polymers, permeation enhancers, microneedles, nano-carriers, and hydrogel-based formulations has overcome several limitations associated with traditional transdermal systems. These innovations have expanded the scope of transdermal delivery for a variety of analgesic and neuropathic drugs.

Furthermore, transdermal drug delivery avoids first-pass metabolism and minimizes gastrointestinal complications, making it a safer and more convenient therapeutic approach for long-term pain management. Although challenges such as skin irritation, variability in permeation, and formulation stability remain, continuous research and technological advancements are expected to address these limitations.

Overall, transdermal drug delivery systems hold immense potential as next-generation therapeutic platforms for chronic pain therapy and may play a vital role in future personalized medicine approaches.

Acknowledgment: Not Applicable.

Funding Statement: The author(s) received no specific funding for this study.

Conflicts of Interest: The authors declare no conflicts of interest to report regarding the present study.

References

- [1] A. B. Anindya, A. W. Alan, and S. C. Sandra, "Sodium channel blockers for the treatment of neuropathic pain," *Neurotherapeutics*, vol. 6, no. 4, pp. 663–678, 2009.
- [2] W. J. Albery and J. Hadgraft, "Percutaneous absorption: In vivo experiments," *J. Pharm. Pharmacol.*, vol. 31, no. 3, pp. 140–147, 1979.
- [3] B. J. Aungst et al., "Contributions of drug solubilization, partitioning, barrier disruption, and solvent permeation to the enhancement of skin permeation of various compounds with fatty acids and amines," *Pharm. Res.*, vol. 7, no. 7, pp. 712–718, 1990.
- [4] R. Alvarez-Roman et al., "Biodegradable polymer nanocapsules containing a sunscreen agent: Preparation and photoprotection," *Eur. J. Pharm. Biopharm.*, vol. 52, no. 2, pp. 191–195, 2001.
- [5] H. C. Ansel, L. V. Allen, and N. G. Popovich, "Transdermal drug delivery systems," in *Pharmaceutical Dosage Forms and Drug Delivery Systems*, 8th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2005, pp. 298–315.
- [6] A. Amit and S. Shubhangi, "Approaches for breaking the barriers of drug permeation through transdermal drug delivery," *J. Control. Release*, vol. 164, no. 1, pp. 26–40, 2012.
- [7] A. V. Arie and W. Wim, "High-performance liquid chromatographic assay of mepivacaine enantiomers in human plasma," *J. Chromatogr. B*, vol. 678, no. 2, pp. 369–372, 1996.

-
- [8] C. S. Asbill and B. B. Michniak, "Percutaneous penetration enhancers: Local versus transdermal activity," *Pharm. Sci. Technol. Today*, vol. 3, no. 1, pp. 36–41, 2000.
- [9] C. Amnuakiet and I. Ikeuchi, "Skin permeation of propranolol from polymeric films containing terpene enhancers," *Int. J. Pharm.*, vol. 289, nos. 1–2, pp. 167–178, 2005.
- [10] R. Amir and C. E. Argoff, "The role of sodium channels in chronic inflammatory and neuropathic pain," *J. Pain*, vol. 7, no. 5, Suppl. 3, pp. S1–S29, 2006.
- [11] A. Arellano and S. Santoyo, "Influence of propylene glycol and isopropyl myristate on the in vitro percutaneous penetration of diclofenac sodium from Carbopol gels," *Eur. J. Pharm. Sci.*, vol. 7, no. 2, pp. 129–135, 1998.
- [12] A. K. M. Huq and S. U. Ahmed, "Design and in-vitro evaluation of compressed Kollidon® SR based salbutamol sulphate microcapsules," *J. Chem. Pharm. Res.*, vol. 3, no. 1, pp. 14–23, 2011.
- [13] M. J. Alvarez-Figueroa and J. Blanco-Méndez, "Transdermal delivery of methotrexate: Iontophoretic delivery from hydrogels and passive delivery from microemulsions," *Int. J. Pharm.*, vol. 215, nos. 1–2, pp. 57–65, 2001.
- [14] A. Azeem and M. Rizwan, "Nanoemulsion components screening and selection," *AAPS PharmSciTech*, vol. 10, no. 1, pp. 69–76, 2009.
- [15] A. Allen and E. Siegfried, "Significant absorption of topical tacrolimus in patients with Netherton syndrome," *Arch. Dermatol.*, vol. 137, no. 6, pp. 747–750, 2001.
- [16] L. Amar and M. Geena, "Topical spray compositions," *U.S. Patent US6962691B1*, 2000.
- [17] W. B. Anthony and A. B. M. Annika, "Models of nociception: Hot-plate, tail-flick, and formalin tests in rodents," *Curr. Protoc. Neurosci.*, pp. 8.9.1–8.9.16, 2007.
- [18] A. T. Adriana and V. L. Valentino, "Eudragit RS 100 microparticles containing cyclodextrin and glutathione," *Eur. J. Pharm. Sci.*, vol. 30, pp. 64–74, 2007.
- [19] H. O. Ammar and M. Ghorab, "Evaluation of chemical penetration enhancers for transdermal delivery of aspirin," *Asian J. Pharm. Sci.*, vol. 3, pp. 96–105, 2007.
- [20] M. C. Alison and M. L. Harriet, "Lidocaine patch 5%," *Drugs*, vol. 59, no. 2, pp. 245–249, 2000.
- [21] M. E. G. Ahmed, H. W. Jun and A. A. Kassem, "In vitro release studies of flurbiprofen from topical formulations," *Drug Dev. Ind. Pharm.*, vol. 28, pp. 823–831, 2002.
- [22] R. Baron, "Neuropathic pain: A clinical perspective," *Nat. Clin. Pract. Neurol.*, vol. 2, no. 2, pp. 95–106, 2006.
- [23] D. Bridges, S. W. Thompson, et al., "Mechanisms of neuropathic pain," *Br. J. Anaesth.*, vol. 87, no. 1, pp. 12–26, 2001.
- [24] A. Beydoun and M. M. Backonja, "Mechanistic stratification of antineuralgic agents," *J. Pain Symptom Manage.*, vol. 25, Suppl. 5, pp. S18–S30, 2003.
- [25] B. Bendas, U. Schmalfuss, and R. Neubert, "Influence of propylene glycol on drug transport from hydrogels," *Int. J. Pharm.*, vol. 116, pp. 19–30, 1995.
- [26] J. A. Bouwstra, "The skin barrier: A well-organized membrane," *Colloids Surf. A*, vol. 123, pp. 403–413, 1997.
- [27] B. W. Barry, "Drug delivery routes in the skin," *Adv. Drug Deliv. Rev.*, vol. 54, Suppl. 1, pp. S31–S40, 2002.
- [28] N. Barker and J. Hadgraft, "Facilitated percutaneous absorption," *Int. J. Pharm.*, vol. 8, no. 3, pp. 193–202, 1981.
- [29] A. Boucaud, "Ultrasound-mediated transdermal drug delivery," *Drug Discov. Today*, vol. 9, no. 19, pp. 827–828, 2004.
- [30] J. T. Beverley and C. F. Barrie, "The transdermal revolution," *Drug Discov. Today*, vol. 9, no. 16,
-

- pp. 697–703, 2004.
- [31] Rekha Gangula, Murali Mohan, and DayakarThalla, “Optimizing Medicine Dosage Recognition through Symptom Intensity Assessment with Support Vector Machines,” *JCAI*, vol. 2, no. 1, pp. 16–25, 2024.
 - [32] A. Bakshi and A. Bajaj, “Metered dose transdermal spray formulation,” *Indian J. Pharm. Sci.*, vol. 70, no. 6, pp. 733–739, 2008.
 - [33] A. J. M. Boulton, “Management of diabetic peripheral neuropathy,” *Clin. Diabetes*, vol. 23, no. 1, pp. 9–15, 2005.
 - [34] K.Vaishali, “Health Education Reimagined Virtual Reality for Immersive Wellness Learning,” *JCESH*, vol. 1, no. 1, pp. 55–66, 2024.
 - [35] I. H. Blank, “Factors influencing water content of stratum corneum,” *J. Invest. Dermatol.*, vol. 18, no. 6, pp. 433–440, 1952.
 - [36] J. Bouwstra and G. Pilgram, “New aspects of skin barrier organization,” *Skin Pharmacol. Appl. Skin Physiol.*, vol. 14, Suppl. 1, pp. 52–62, 2001.
 - [37] R. O. Bailey and A. L. Baltch, “Sensory motor neuropathy in AIDS,” *Neurology*, vol. 38, no. 6, pp. 886–891, 1988.